Secondary Patenting of Branded Pharmaceuticals
October 10, 2012 | Journal Article
This article examines how secondary patents can extend market exclusivity and thus delay generic competition.
You are now viewing 1 - 10 of 168 results
October 10, 2012 | Journal Article
This article examines how secondary patents can extend market exclusivity and thus delay generic competition.
October 8, 2012 | Journal Article
Under FDA policy, communications by prescription drug manufacturers must be backed by “substantial evidence” from “adequate and well-controlled investigations.” But numerous exceptions permit manufacturer promotion based on data other than randomized trials.
October 4, 2012 | Journal Article
This perspective examines the Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) of 2012.
October 1, 2012 | Journal Article
This study examines how different drug plan benefit and formulary designs influence the selection of generic drugs to treat high cholesterol among Medicare beneficiaries.
August 1, 2012 | Journal Article
While the 1983 Orphan Drug Act led to a boom in development and production of orphan drugs, inattentive regulatory standards may imperil patients with rare diseases.
May 1, 2012 | Journal Article
Value-based insurance design bases cost sharing on a medication's clinical value, not its price. This study shows the effectiveness of value-based insurance design.
October 12, 2012 | Story
Drug patent reform and legal restrictions on pharmaceutical company advertising are explored in an RWJF Investigator’s latest research.
April 1, 2012 | Journal Article
Amid calls for physicians to become better stewards of the nation's health care resources, it is important to gain insight into how physicians think about the cost-effectiveness of new treatments.
December 1, 2011 | Journal Article
Study found use of free drug samples widespread among older adults but participation in pharmaceutical industry-sponsored patient assistance programs very low.
September 1, 2011 | Journal Article
Using market exclusivity to promote pharmaceutical innovation can lead to positive outcomes, but the practice is also characterized by waste and collateral effects.